INS and Alzheimer disease: After icv administration, STZ alters enzymes involved in the glycolytic cerebral metabolism of glucose [6], [7], [8] and insulin/IGF pathway therefore leading to an insulin resistance brain state that mimics some of the cerebral alterations occurring in AD [9], [10], [11], [12].